Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Chromacode Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners, meaning that each active case is under the review of a different individual. Despite having multiple examiners, the portfolio is concentrated within 1 distinct art unit. This suggests that the company's current filings are technically similar enough to be grouped together by the patent office, even if they are handled by different people. SAMUEL C WOOLWINE is the busiest examiner for the company, managing 1 pending office action.
Since there are 2 pending actions in total, each of the distinct examiners is responsible for a single action. Practitioners can focus their efforts on the specific standards of the 1 distinct art unit involved, while still needing to tailor their arguments to the individual preferences of different examiners. This structure provides a relatively stable prosecution environment within the Biotechnology & Pharmaceuticals field, as the company only needs to navigate the policies of a single art unit. The pending office actions represent a balanced distribution of work between the distinct examiners currently assigned to the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WOOLWINE, SAMUEL C | 1 | 61.0% | +20.3% |
| KIM, YOUNG J | 1 | 64.8% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18661539 | DETECTION OF DONOR DNA IN TRANSPLANT RECIPIENT BIO-SAMPLE | KIM, YOUNG J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18890542 | MULTIPLEXED FLUOROMETRIC MEASUREMENTS WITH DROPLET PCR SYSTEMS | WOOLWINE, SAMUEL C | — |
| 18661539 | DETECTION OF DONOR DNA IN TRANSPLANT RECIPIENT BIO-SAMPLE | KIM, YOUNG J | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18890542 | MULTIPLEXED FLUOROMETRIC MEASUREMENTS WITH DROPLET PCR SYSTEMS | WOOLWINE, SAMUEL C | 1681 | §103 | Non-Final OA | — | Pending | Sep 19, 2024 |
| 18661539 | DETECTION OF DONOR DNA IN TRANSPLANT RECIPIENT BIO-SAMPLE | KIM, YOUNG J | — | §103§112 | Non-Final OA | — | Pending | May 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChromacode Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Samuel C Woolwine has the most, with 1 of Chromacode Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
